Cubist Systematic Strategies’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-52,794
| Closed | -$1.66M | – | 3538 |
|
|
2025
Q2 | $1.66M | Sell |
52,794
-96,695
| -65% | -$3.1M | 0.01% | 1658 |
|
|
2025
Q1 | $4.9M | Buy |
149,489
+9,967
| +7% | +$353K | 0.03% | 892 |
|
|
2024
Q4 | $5.05M | Buy |
139,522
+126,161
| +944% | +$4.44M | 0.03% | 832 |
|
|
2024
Q3 | $417K | Sell |
13,361
-66,271
| -83% | -$2.07M | ﹤0.01% | 2282 |
|
|
2024
Q2 | $2.13M | Buy |
79,632
+39,479
| +98% | +$1.14M | 0.01% | 1293 |
|
|
2024
Q1 | $1.37M | Sell |
40,153
-1,383
| -3% | -$41.2K | 0.01% | 1916 |
|
|
2023
Q4 | $1.2M | Buy |
+41,536
| New | +$1.1M | 0.01% | 1909 |
|
|
2023
Q2 | – | Sell |
-71,623
| Closed | -$2.59M | – | 4278 |
|
|
2023
Q1 | $2.59M | Buy |
71,623
+63,569
| +789% | +$2.44M | 0.02% | 1453 |
|
|
2022
Q4 | $287K | Sell |
8,054
-22,681
| -74% | -$788K | ﹤0.01% | 3386 |
|
|
2022
Q3 | $1.04M | Buy |
+30,735
| New | +$1M | 0.01% | 2593 |
|
|
2022
Q2 | – | Sell |
-17,667
| Closed | -$571K | – | 4566 |
|
|
2022
Q1 | $571K | Sell |
17,667
-57,636
| -77% | -$1.77M | ﹤0.01% | 2446 |
|
|
2021
Q4 | $2.2M | Buy |
+75,303
| New | +$2.28M | 0.02% | 1280 |
|
|
2021
Q3 | – | Sell |
-7,692
| Closed | -$237K | – | 3164 |
|
|
2021
Q2 | $237K | Buy |
+7,692
| New | +$236K | ﹤0.01% | 2460 |
|
|
2021
Q1 | – | Sell |
-47,280
| Closed | -$1.19M | – | 2970 |
|
|
2020
Q4 | $1.19M | Buy |
+47,280
| New | +$1.02M | 0.02% | 1266 |
|
|
2020
Q3 | – | Sell |
-62,091
| Closed | -$1.48M | – | 2631 |
|
|
2020
Q2 | $1.48M | Buy |
62,091
+34,859
| +128% | +$770K | 0.03% | 969 |
|
|
2020
Q1 | $490K | Buy |
27,232
+1,751
| +7% | +$36.8K | 0.01% | 1272 |
|
|
2019
Q4 | $604K | Buy |
25,481
+13,402
| +111% | +$325K | 0.01% | 1437 |
|
|
2019
Q3 | $332K | Sell |
12,079
-22,545
| -65% | -$668K | 0.01% | 1504 |
|
|
2019
Q2 | $1.15M | Buy |
34,624
+5,925
| +21% | +$203K | 0.02% | 965 |
|
|
2019
Q1 | $1.01M | Buy |
28,699
+9,882
| +53% | +$368K | 0.03% | 761 |
|
|
2018
Q4 | $625K | Buy |
18,817
+9,195
| +96% | +$395K | 0.03% | 822 |
|
|
2018
Q3 | $484K | Buy |
9,622
+6,222
| +183% | +$307K | 0.03% | 849 |
|
|
2018
Q2 | $203K | Buy |
+3,400
| New | +$176K | 0.01% | 1350 |
|
|
2018
Q1 | – | Sell |
-7,356
| Closed | -$293K | – | 2061 |
|
|
2017
Q4 | $293K | Buy |
+7,356
| New | +$291K | 0.02% | 1263 |
|
|
2017
Q1 | – | Sell |
-2,871
| Closed | -$72K | – | 1854 |
|
|
2016
Q4 | $72K | Sell |
2,871
-13,028
| -82% | -$291K | 0.01% | 1536 |
|
|
2016
Q3 | $393K | Buy |
15,899
+3,419
| +27% | +$77.4K | 0.03% | 829 |
|
|
2016
Q2 | $254K | Buy |
12,480
+2,761
| +28% | +$49K | 0.01% | 1186 |
|
|
2016
Q1 | $148K | Sell |
9,719
-4,034
| -29% | -$52.6K | 0.01% | 1321 |
|
|
2015
Q4 | $185K | Sell |
13,753
-15,112
| -52% | -$234K | 0.01% | 1384 |
|
|
2015
Q3 | $405K | Sell |
28,865
-11,602
| -29% | -$216K | 0.02% | 1081 |
|
|
2015
Q2 | $687K | Buy |
+40,467
| New | +$576K | 0.03% | 778 |
|
|
2015
Q1 | – | Sell |
-16,252
| Closed | -$135K | – | 2069 |
|
|
2014
Q4 | $135K | Sell |
16,252
-6,603
| -29% | -$55.5K | 0.01% | 1637 |
|
|
2014
Q3 | $199K | Buy |
+22,855
| New | +$206K | 0.01% | 1379 |
|
Other funds holding SUPN
AC
Cubist Systematic Strategies's SUPN Position: Q3 2025 in Review
Cubist Systematic Strategies sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 52,794 shares — an estimated $1.66M sold.
Cubist Systematic Strategies first reported a position in SUPN in Q3 2014 and held it in 33 quarters. The position peaked at $5.05M in Q4 2024. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.
- Cubist Systematic Strategies reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Cubist Systematic Strategies sold 52,794 Supernus Pharmaceuticals shares in Q3 2025, an estimated $1.66M.
- Cubist Systematic Strategies first reported a position in Supernus Pharmaceuticals in Q3 2014 and held it in 33 quarters.
- Cubist Systematic Strategies's Supernus Pharmaceuticals position peaked at $5.05M in Q4 2024.
- 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.